CRISPR Therapeutics AG ($CRSP) Stock Forecast: Up 6.3% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics (CRSP) is a gene-editing company that focuses on developing transformative gene-based medicines for serious diseases. The company's stock had a strong bullish movement today.

Why is CRISPR Therapeutics AG going up?

CRSP stock is up 6.3% on Jan 23, 2026 14:45

• An insider's sale of shares worth $5.2 million initially raised some concerns among investors, causing a slight dip in the stock price during premarket trading.
• Despite the selling activity, the positive announcement of Casgevy therapy exceeding $100 million in revenue by 2025 and the expected regulatory submissions for younger patients with specific ailments bolstered investor confidence, leading to a significant increase in the stock price.
• Varying analyst opinions and valuation methods indicate short-term fluctuations due to insider transactions, but the long-term growth potential and advancements in gene editing technology position CRISPR Therapeutics for sustained success in the gene therapy sector.
• Taken together, the CEO's share sale, favorable revenue updates, progress in clinical trials, and expert analyses likely drove the upward momentum in CRSP stock today.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics (NASDAQ: CRSP) shares slipped in premarket trading after an 11.1% surge the previous day, influenced by an SEC filing revealing CEO Samarth Kulkarni sold 90,000 shares totaling $5.2 million under a pre-arranged plan. Despite the insider sale and a trimmed price target from Bank of America, options trading activity increased, keeping the gene-editing stock in focus. The company's Casgevy therapy, developed with Vertex Pharmaceuticals, surpassed $100 million in revenue in 2025, but its commercial rollout, dependent on complex hospital protocols and reimbursement, remains a key variable for investors.

https://ts2.tech/en/crispr-therapeutics-stock-in-focus-as-shares-cool-premarket-after-11-surge-and-ceo-sale-filing/

Samarth Kulkarni Sells 60,000 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

Samarth Kulkarni, CEO of CRISPR Therapeutics (NASDAQ:CRSP), sold 60,000 shares of the company's stock for over $3.6 million, reducing his position by 30.9%. This transaction occurred on January 22nd, with shares trading up 10.8% on high volume. Analyst sentiment for CRSP is mixed, with a consensus "Hold" rating and an average price target of $68.35, despite the company beating EPS estimates but missing revenue significantly in its last quarterly report.

https://www.marketbeat.com/instant-alerts/samarth-kulkarni-sells-60000-shares-of-crispr-therapeutics-nasdaqcrsp-stock-2026-01-22/

Casgevy Revenue Surge and Clinical Advancements Bolster CRISPR Therapeutics’ Market Position

CRISPR Therapeutics (CRSP) saw its stock rise by 9.84% following a strong quarterly earnings report, with Casgevy's revenue surpassing $100 million in 2025. The company anticipates regulatory submissions for Casgevy in younger patients with Sickle Cell Disease and Transfusion-Dependent Thalassemia by mid-2026. This growth, coupled with advancements in its CTX310 program and a positive Buy rating from Bank of America, reinforces investor confidence and positions CRISPR for continued market dominance in gene therapy.

https://stockstotrade.com/news/crispr-therapeutics-ag-crsp-news-2026_01_22/

Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Gene Editing Progress?

This article evaluates CRISPR Therapeutics (CRSP) following recent gene editing advancements, using two valuation methods. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 73.4%, with an estimated intrinsic value of US$201.16 compared to its current price of US$53.51. The Price-to-Book (P/B) ratio indicates the stock is "about right" when compared to the industry average, though a proprietary "Fair Ratio" is unavailable.

https://www.sahmcapital.com/news/content/is-it-time-to-reassess-crispr-therapeutics-crsp-after-recent-gene-editing-progress-2026-01-17

Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and Crispr Therapeutics AG (CRSP)

This article summarizes recent analyst ratings for healthcare companies Radnet (RDNT) and Crispr Therapeutics AG (CRSP). Jefferies maintained a Buy rating on Radnet with a $91.00 price target, while KeyBanc also initiated coverage with a Buy rating and a $92.00 target. Bernstein maintained a Hold rating on Crispr Therapeutics AG with a $50.00 price target, though TipRanks – OpenAI upgraded the stock to Hold with a $56.00 target.

https://www.theglobeandmail.com/investing/markets/stocks/CRSP-Q/pressreleases/37082181/analysts-offer-insights-on-healthcare-companies-radnet-rdnt-and-crispr-therapeutics-ag-crsp/

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 5.9% Today

Chiliz ($CHZ) Crypto Forecast: Down 12.2% Today

Worldcoin ($WLD) Crypto Forecast: Down 9.6% Today

XRP ($XRP) Crypto Forecast: Down 6.1% Today

Ethereum ($ETH) Crypto Forecast: Down 7.0% Today

Copper ($COPPER) Commodity Forecast: Down 6.1% Today

Gold ($XAU) Commodity Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Down 7.2% Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 7.1% Today

CRISPR Therapeutics AG Price History

10.09.2025 - CRSP Stock was down 5.1%

• CRSP stock saw a significant bearish movement, dropping by 6.98% to close at $67.74.
• The stock's decline was more pronounced than the broader market trend, indicating specific factors impacting CRISPR Therapeutics AG.
• The dip in CRSP stock could be attributed to potential concerns over the company's research and development pipeline or general market volatility affecting biotech stocks.
• Investors may be closely monitoring any updates on CRISPR Therapeutics' clinical trials, regulatory approvals, or competitive landscape to gauge the stock's future performance.

31.09.2025 - CRSP Stock was up 5.8%

• Despite a -2.51% change from the previous close, the market movement for CRSP today was bullish.
• The slight decrease in stock price may be due to profit-taking by some investors following a recent uptrend.
• Positive sentiment towards the company's gene-editing technology and future growth prospects likely fueled the bullish movement.
• Investors' optimism about CRSP's pipeline of gene therapies and their potential to address unmet medical needs could be boosting the stock price.

22.11.2025 - CRSP Stock was up 5.2%

• The recent rise in CRSP stock value may be linked to a reevaluation of the company's worth following a recent decline, highlighting its strong performance so far this year and potential undervaluation based on a Discounted Cash Flow model.
• Despite concerns about the slow adoption of its gene-editing therapy Casgevy, there appears to be a positive outlook on CRISPR Therapeutics' future prospects, particularly given the stock's strong performance compared to its sector and the broader market in the past month.
• Anticipated lower earnings and revenue in the upcoming financial report may have already been considered in the stock price, leading to increased optimism among investors who are focusing on the long-term potential of CRISPR Therapeutics' project portfolio rather than short-term obstacles.

06.09.2025 - CRSP Stock was up 5.0%

• Factors contributing to the rise in CRSP stock today include:
• Despite a recent stock decline, the overall market trend indicates investor optimism towards the future of CRISPR Therapeutics AG.
• The -6.98% change from the previous close could be a temporary adjustment, presenting an opportunity for investors interested in benefiting from the decrease.
• It's important for investors to monitor developments in the CRISPR technology sector closely, as progress or regulatory authorizations could have a significant impact on CRSP stock in the future.

22.09.2025 - CRSP Stock was down 6.3%

• Today's downward trend in CRSP stock could be linked to profit-taking by investors following a recent uptick in its price.
• The -2.24% drop might also be influenced by broader market sentiments or shifts within the biotech sector.
• Investor reactions may be tied to potential negative updates or uncertainties surrounding the company's clinical trials, regulatory challenges, or competitive landscape in gene editing.
• It is crucial for investors to stay informed about the company's pipeline progress and regulatory changes to evaluate the future trajectory of CRSP stock.

06.00.2026 - CRSP Stock was up 5.5%

• Today's upward movement in CRSP stock is linked to the increased investor interest post its participation in the J.P. Morgan Healthcare Conference, highlighting groundbreaking medicines like CASGEVY®.
• The company's perceived undervaluation, evident in its price-to-book ratio and discounted cash flow model in comparison to competitors, has likely attracted investors seeking potential growth opportunities.
• Although the stock recently experienced a decline relative to the broader market, the upcoming earnings report, forecasting an EPS of -$1.16 and revenue of $4 million, holds promise for a potential turnaround in the stock's performance.
• The endorsement from Chardan to buy shares further contributes to the positive outlook on CRSP, signifying faith in the company's future trajectory and growth possibilities.

06.00.2026 - CRSP Stock was up 10.9%

• Investor interest in CRISPR Therapeutics is growing due to its undervalued position in comparison to peers and its intrinsic value, despite sustained losses.
• Although there was a recent decline in the stock price, upcoming earnings are expected to be slightly negative according to analysts, prompting investors to closely monitor future performance.
• Key factors for potential stock movements include the company's collaboration with Vertex Pharmaceuticals and the introduction of its gene-editing therapy, Casgevy.
• Chardan's reiterated "buy" recommendation and positive clinical updates on Zugo-cel are bolstering the bullish momentum in CRSP stock.

10.10.2025 - CRSP Stock was down 5.0%

• CRSP stock dropped by -2.56% despite overall market gains.
• The bearish movement may be due to profit-taking by investors after a growth period.
• Concerns about the company's future earnings potential or regulatory challenges could be influencing investors.
• Monitoring upcoming developments in the biotech sector that could affect CRSP's stock performance is important.

23.00.2026 - CRSP Stock was up 6.3%

• An insider's sale of shares worth $5.2 million initially raised some concerns among investors, causing a slight dip in the stock price during premarket trading.
• Despite the selling activity, the positive announcement of Casgevy therapy exceeding $100 million in revenue by 2025 and the expected regulatory submissions for younger patients with specific ailments bolstered investor confidence, leading to a significant increase in the stock price.
• Varying analyst opinions and valuation methods indicate short-term fluctuations due to insider transactions, but the long-term growth potential and advancements in gene editing technology position CRISPR Therapeutics for sustained success in the gene therapy sector.
• Taken together, the CEO's share sale, favorable revenue updates, progress in clinical trials, and expert analyses likely drove the upward momentum in CRSP stock today.

22.00.2026 - CRSP Stock was up 6.2%

• CRISPR Therapeutics (CRSP) saw a significant uptrend in its stock performance today, potentially influenced by the following key factors:
• Recent advancements in gene editing have instilled optimism among investors, leading to a notable undervaluation of the company based on a Discounted Cash Flow analysis.
• Various analyst ratings, including a Buy recommendation from Bank of America Securities with a target price of $90.00, have also positively impacted market sentiment towards CRSP.
• A substantial 455.7% increase in stake by Nwam LLC during Q3 could be interpreted as a vote of confidence in the company's long-term outlook, despite falling short of revenue expectations in the same period.
• The unveiling of CRISPR Therapeutics' 2026 strategic roadmap, emphasizing global commercialization efforts and regulatory submissions, has offered investors a peek into potential future growth prospects, helping to counter recent declines in the stock price.

14.09.2025 - CRSP Stock was down 10.4%

• CRSP stock saw a more significant decline compared to the broader market, ending at $68.29, reflecting a -6.54% change from the previous day, indicating a bearish trend.
• The stock's notable drop could be linked to profit-taking activities by investors following a recent price surge or concerns regarding the company's pipeline or financial results.
• Despite the market's positive performance, specific internal factors within CRSP such as regulatory challenges, clinical trial outcomes, or alterations in analyst outlooks might have influenced its stock decline.
• Investors are likely keeping a close watch on developments in the biotech industry and updates on CRISPR technology that could impact CRSP's stock movement in the near future.

08.00.2026 - CRSP Stock was down 5.3%

• The bearish movement in CRISPR Therapeutics AG (CRSP) today could be due to:
• Despite positive sentiment from institutional investors and analyst recommendations, the stock may have experienced profit-taking after a significant gain in market cap last week.
• The varying assessments of the stock's valuation, with a DCF analysis pointing towards undervaluation and the P/B ratio indicating fair pricing, might have resulted in investor uncertainty.
• Investor interest and attention refocusing on CRSP could have led to increased volatility as market participants reassess the company's potential growth opportunities and risks linked to its pipeline programs.
• The anticipation surrounding the upcoming presentation at the J.P. Morgan Healthcare Conference may have heightened expectations, prompting a sell-off as investors await further details or guidance from the management team.